ZA200603221B - Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders - Google Patents

Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders

Info

Publication number
ZA200603221B
ZA200603221B ZA200603221A ZA200603221A ZA200603221B ZA 200603221 B ZA200603221 B ZA 200603221B ZA 200603221 A ZA200603221 A ZA 200603221A ZA 200603221 A ZA200603221 A ZA 200603221A ZA 200603221 B ZA200603221 B ZA 200603221B
Authority
ZA
South Africa
Prior art keywords
glyt
triaza
neurological
inhibitors
treatment
Prior art date
Application number
ZA200603221A
Other languages
English (en)
Inventor
Ceccarelli Simona Maria
Stalder Henri
Pinard Emmanuel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200603221B publication Critical patent/ZA200603221B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200603221A 2003-10-23 2006-04-21 Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders ZA200603221B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03024415 2003-10-23

Publications (1)

Publication Number Publication Date
ZA200603221B true ZA200603221B (en) 2009-04-29

Family

ID=34486099

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603221A ZA200603221B (en) 2003-10-23 2006-04-21 Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders

Country Status (19)

Country Link
US (1) US7189850B2 (ja)
EP (1) EP1678177B1 (ja)
JP (1) JP4490434B2 (ja)
KR (1) KR100798161B1 (ja)
CN (1) CN100467468C (ja)
AR (1) AR046186A1 (ja)
AU (1) AU2004283843B2 (ja)
BR (1) BRPI0415833A (ja)
CA (1) CA2543308C (ja)
CO (1) CO5690643A2 (ja)
DE (1) DE602004010419T2 (ja)
ES (1) ES2297502T3 (ja)
IL (1) IL174734A (ja)
MX (1) MXPA06004305A (ja)
NO (1) NO20061419L (ja)
RU (1) RU2006117368A (ja)
TW (1) TW200526662A (ja)
WO (1) WO2005040166A1 (ja)
ZA (1) ZA200603221B (ja)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5266042B2 (ja) * 2005-04-11 2013-08-21 エール ユニヴァーシティ 統合失調症前駆症の治療方法
DE102005038141A1 (de) * 2005-08-12 2007-02-15 Grünenthal GmbH Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate
CA2642859A1 (en) * 2006-03-08 2007-09-13 F. Hoffmann-La Roche Ag 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones
EP2004612A1 (en) * 2006-03-16 2008-12-24 Glaxo Group Limited N-phenyl-2-0x0-1,4-diazaspir0 [4.5]dec-3-en-1-yl acetamide derivatives and their use as glycine transporter inhibitors
GB0607398D0 (en) * 2006-04-12 2006-05-24 Glaxo Group Ltd Compounds
EP2035420A2 (en) * 2006-06-20 2009-03-18 Wyeth a Corporation of the State of Delaware Kv1.5 potassium channel inhibitors
JP2010517961A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
JP2010517964A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
JP2010517959A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
WO2008092877A2 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited 8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
GB0701955D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
GB0701985D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
WO2008092876A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
RU2470011C2 (ru) 2007-05-31 2012-12-20 Сепракор Инк. Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
AU2008270444A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
MX2009014235A (es) 2007-08-22 2010-04-27 Abbott Gmbh & Co Kg 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
WO2009034062A1 (en) * 2007-09-11 2009-03-19 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof in medicine
US20090077077A1 (en) * 2007-09-18 2009-03-19 Gerhard Geldenbott Optimal selection of MSAG address for valid civic/postal address
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
MX2010010773A (es) 2008-04-01 2011-04-11 Abbott Gmbh & Co Kg Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia.
MA32947B1 (fr) 2009-01-27 2012-01-02 Hoffmann La Roche Piperidines substitues par aroylamino et heteroaroylamino comme inhibiteurs de glyt-1
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
SG189525A1 (en) 2010-10-25 2013-05-31 G1 Therapeutics Inc Cdk inhibitors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
TW201319049A (zh) 2011-08-05 2013-05-16 Abbott Gmbh & Co Kg 胺基□唍、胺基硫□唍及胺基－１，２，３，４－四氫喹啉衍生物，包含彼等之醫藥組合物及彼等於治療之用途
CA2853254A1 (en) 2011-11-18 2013-05-23 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
JP2015157764A (ja) * 2012-06-14 2015-09-03 大正製薬株式会社 グリシントランスポーター阻害物質
JP6430483B2 (ja) 2013-03-15 2018-11-28 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法の間の正常細胞の一時的な保護
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014144740A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336153A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336154A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015103060A1 (en) 2014-01-06 2015-07-09 Algomedix, Inc. Trpa1 modulators
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
TWI601712B (zh) 2014-11-05 2017-10-11 達特神經科學（開曼）有限責任公司 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物
CR20180443A (es) 2016-03-17 2018-11-21 Hoffmann La Roche Derivado de morfolina
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
NZ754865A (en) 2017-01-06 2023-07-28 G1 Therapeutics Inc Combination therapy for the treatment of cancer
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. MORPHIC FORMS OF GIT38 AND METHODS OF MAKING SAME
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0921125T1 (en) * 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
ATE340782T1 (de) * 2003-02-17 2006-10-15 Hoffmann La Roche Piperidinbenzolsulfonamidderivate

Also Published As

Publication number Publication date
US7189850B2 (en) 2007-03-13
RU2006117368A (ru) 2007-12-10
WO2005040166A1 (en) 2005-05-06
JP4490434B2 (ja) 2010-06-23
TW200526662A (en) 2005-08-16
BRPI0415833A (pt) 2007-01-02
KR20060076317A (ko) 2006-07-04
IL174734A0 (en) 2006-08-20
CO5690643A2 (es) 2006-10-31
AU2004283843B2 (en) 2010-04-22
CA2543308A1 (en) 2005-05-06
CN1871238A (zh) 2006-11-29
DE602004010419D1 (de) 2008-01-10
AR046186A1 (es) 2005-11-30
DE602004010419T2 (de) 2008-10-09
EP1678177A1 (en) 2006-07-12
NO20061419L (no) 2006-07-14
ES2297502T3 (es) 2008-05-01
KR100798161B1 (ko) 2008-01-28
EP1678177B1 (en) 2007-11-28
MXPA06004305A (es) 2006-06-05
CA2543308C (en) 2012-03-06
US20050107373A1 (en) 2005-05-19
CN100467468C (zh) 2009-03-11
AU2004283843A1 (en) 2005-05-06
IL174734A (en) 2010-05-31
JP2007509097A (ja) 2007-04-12

Similar Documents

Publication Publication Date Title
ZA200603221B (en) Triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
HK1090634A1 (en) Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
HK1078858A1 (en) Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders
ZA200705123B (en) Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
HK1079203A1 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
AU2002352483A1 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
ZA200704089B (en) Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation
HK1089155A1 (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
IL169091A0 (en) Benzazepine derivatives for the treatment of neurological disorders
ZA200700223B (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-peperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders
AU2003286567A8 (en) Methods for the treatment of skin disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
PL374700A1 (en) Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
ZA200705472B (en) [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted-phenyl) methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
EP1664051A4 (en) PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USING SAME FOR TREATING PROLIFERATION DISORDERS
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
IL165394A0 (en) Use of thio-oxindole derivatives in treatment of skin disorders
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
IL172018A0 (en) Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases
GB0321384D0 (en) Pteridine derivatives for the treatment of septic shock and TNF-alpha- related diseases
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
AU2003253130A1 (en) Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders